Gyeonggawon Transfers Bio-Held Technologies to Private Sector... Osteoporosis Treatment Candidate Substances Included

Yoo Seung-kyung, President of Gyeonggi-do Economic Science Promotion Agency (second from left), is attending the signing ceremony of the "Bio Technology Transfer and Research Cooperation Agreement" held on the 20th at the Gyeonggi-do Bio Center in Suwon, taking a commemorative photo with the officials.

[Asia Economy (Suwon) = Reporter Lee Young-gyu] The Gyeonggi-do Economic Science Promotion Agency is transferring bio-related technologies, including candidate substances for osteoporosis treatment, to private companies.

On the 20th, the agency announced on the 21st that it signed a "Business Agreement for Bio Technology Transfer and Research Cooperation" at the agency's Bio Center in Gwanggyo Technovalley, Suwon, to foster the pharmaceutical and bio industries in the province.

The signing ceremony was held to support the commercialization success of new drugs and functional product development by transferring bio-platform technologies developed by the agency, supported by Gyeonggi Province, to bio companies in the province.

The technologies transferred on this day include three types: candidate substances for osteoporosis treatment, candidate substances for lymphedema treatment, and compositions related to skin wrinkle improvement.

The candidate substance for osteoporosis treatment is a material that promotes bone formation and inhibits bone resorption, jointly developed in 2017 by Dr. Gu Jin-mo of the agency's Bio Center and CEO Park Gil-hong of GH Pharm Co., Ltd. Currently, patents have been filed not only domestically but also in three overseas countries including the United States, Europe, and China.

The candidate substance for lymphedema treatment is expected to become the world's first specialized pharmaceutical for lymphedema by fundamentally preventing and treating the pathological features of lymphedema, which progresses through inflammation, fat accumulation, and fibrosis.

The technology transfer of the composition for skin wrinkle improvement, promoted by the agency's efficacy evaluation team, is a research outcome of the ABS response biological material support project by the National Institute of Biological Resources under the Ministry of Environment. Through non-clinical research on overseas natural useful biological resources, a composition for improving skin wrinkles and erythema was developed and a domestic patent was registered in 2018.

Yoo Seung-kyung, director of the agency, said, "This technology transfer is the result of accumulated expertise and technical capabilities of researchers built over the past 10 years of continuous corporate support work at the agency's Bio Center." He added, "Going forward, the agency will do its best to actively promote collaboration with academia, research institutes, and local companies to advance bio-technology in Gyeonggi Province."

This content was produced with the assistance of AI translation services.